| Patent Number |
Title Of Patent |
Date Issued |
| 6846476 |
Treatment of B-cell associated diseases |
January 25, 2005 |
| Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN.RTM. and a radiolabeled anti-CD22 antibody, preferably an .sup.90 Y labeled humanized anti-CD22 antibody, |
| 6841383 |
Method for integrating genes at specific sites in mammalian cells via homologous recombination a |
January 11, 2005 |
| A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally act |
| 6682734 |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted |
January 27, 2004 |
| Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 |
| 6506383 |
Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific an |
January 14, 2003 |
| The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases. |
| 6455043 |
Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
September 24, 2002 |
| New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas. |
| 6451284 |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
September 17, 2002 |
| New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow. |
| 6440418 |
Methods of treating autoimmune diseases with gp39-specific antibodies |
August 27, 2002 |
| The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or |
| 6413771 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
July 2, 2002 |
| A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are pr |
| 6300143 |
Electrochemiluminescent assays for eukaryotic cells |
October 9, 2001 |
| Disclosed are immunomagnetic electrochemiluminescence assays for eukaryotic cells, particularly human cells. A competitive binding assay is disclosed which enables affinity measurements of antibodies specific for eukaryotic cell membrane proteins. Such an assay is particularly useful for |
| 6270769 |
Induction of cytotoxic T-lymphocyte responses |
August 7, 2001 |
| Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which c |
| 6207858 |
Regioselective synthesis of DTPA derivatives |
March 27, 2001 |
| The present invention provides a process for high yield regioselective synthesis of DTPA derivatives that eliminates the need for ion exchange chromotographic separation of intermediates. Moreover, as this process yields a single regioisomer of the chelate, it provides for the regios |
| 6197311 |
Induction of cytotoxic T-lymphocyte responses |
March 6, 2001 |
| Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formu |
| 6136310 |
Recombinant anti-CD4 antibodies for human therapy |
October 24, 2000 |
| Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma |
| 6113898 |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
September 5, 2000 |
| The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention provides four monkey |
| 6017733 |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement o |
January 25, 2000 |
| Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector, These vectors are most typically utilized in the expression of proteins in mammalian express |
| 6011138 |
Gamma-1 anti-human CD23 monoclonal antibodies |
January 4, 2000 |
| Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains. |
| 6001358 |
Humanized antibodies to human gp39, compositions containing thereof |
December 14, 1999 |
| The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases. |
| 5998144 |
Method for integrating genes at specific sites in mammalian cells via homologous recombination a |
December 7, 1999 |
| A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally act |
| 5958765 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
September 28, 1999 |
| A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are pr |
| 5955364 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
September 21, 1999 |
| Novel human monoclonal antibodies, and their corresponding nucleic acid sequences having high affinity for the human RSV-F protein are provided. |
| 5939068 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
August 17, 1999 |
| A method of detecting RSV (Respiratory Syncytial Virus) in an analyte using high affinity human monoclonal antibodies is provided. |
| 5866125 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
February 2, 1999 |
| A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided. |
| 5840298 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
November 24, 1998 |
| A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided. |
| 5830698 |
Method for integrating genes at specific sites in mammalian cells via homologous recombination a |
November 3, 1998 |
| A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally act |
| 5811524 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for |
September 22, 1998 |
| A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are pr |
| 5776456 |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted |
July 7, 1998 |
| Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 |
| 5756096 |
Recombinant antibodies for human therapy |
May 26, 1998 |
| Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use. |
| 5750105 |
Recombinant antibodies for human therapy |
May 12, 1998 |
| Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use. |
| 5736137 |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted |
April 7, 1998 |
| Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 |
| 5733779 |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement o |
March 31, 1998 |
| Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian express |
| 5709860 |
Induction of cytotoxic T-lymphocyte responses |
January 20, 1998 |
| Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which c |
| 5695770 |
Induction of cytotoxic T-lymphocyte responses |
December 9, 1997 |
| Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which c |
| 5693780 |
Recombinant antibodies for human therapy |
December 2, 1997 |
| Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use. |
| 5681722 |
Recombinant antibodies for human therapy |
October 28, 1997 |
| Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use. |
| 5658570 |
Recombinant antibodies for human therapy |
August 19, 1997 |
| Chimeric antibodies including an Old World monkey portion and a human portion, nucleic acid encoding such antibodies, Old World monkey monoclonal antibodies, and methods for their production and use. |
| 5648267 |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement o |
July 15, 1997 |
| Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector. These vectors are most typically utilized in the expression of proteins in mammalian express |
